After 40 Years In Nutritional Biochemistry, This Is What I Wish Every Newly Diagnosed Patient Knew About Their Blood Pressure.
A retrospective from the Chief Science Officer of a longevity research company, drawing from four decades of work in the field. The science is settled. The conversation in your doctor's office should look different than it does.
Dr. Luke Bucci, PhD, Chief Science Officer at Juvenon. Forty years in nutritional biochemistry. Has mapped 13 of Juvenon's 46 nutrients to Nobel-Prize-winning research.
I have spent forty years in nutritional biochemistry.
I have a PhD. I have published. I have served as a senior scientist or science officer at four supplement and longevity companies. I have read more papers on cardiovascular signaling than I can reasonably count, and at this point in my career, I have stopped being surprised by what newly diagnosed patients are not told at their first appointment.
I want to use this article to say what I would say to a newly diagnosed patient if they sat across from me at my desk for an hour, instead of across from their doctor for ten minutes.
I am not here to undermine your doctor. Your doctor is doing the job their schedule allows them to do. They are not lying to you. They are triaging. There is a difference.
But there are things I know, after forty years in this field, that I think every newly diagnosed patient deserves to hear plainly. Here they are.
What Your Doctor Is Treating Versus What Is Actually Happening
When your physician hands you a prescription for blood pressure medication, what they are doing, in technical terms, is targeting one of two downstream regulatory systems. Most commonly the renin-angiotensin-aldosterone system, or the calcium channel system in your blood vessel smooth muscle. These are good targets. The drugs that hit them are well-studied and largely work.
But blood pressure is not produced by just two systems. It is produced by at least six. Heart contraction force. Blood vessel diameter. Total blood volume. Kidney filtration. Autonomic nervous system tone. Endothelial function.
Of those six, the standard prescription addresses two. The other four are doing whatever they are doing, and largely going unaddressed.
That is not a criticism of medication. Medication is doing its part. It is a description of what medication is, and what it is not.
The standard prescription is doing what it is designed to do. It is addressing two of the six systems that govern blood pressure. The patient who learns to address the other four is the patient who feels noticeably better.
The Discovery That Changed Cardiovascular Science (And Did Not Make It Into Patient Education)
In 1998 the Nobel Prize in Physiology or Medicine was awarded for the discovery of nitric oxide as a signaling molecule in the cardiovascular system. This was, in our field, a landmark event. It rewrote a fundamental chapter of how we understand blood vessel function.
To summarize. Your blood vessels are not passive plumbing. They are active. They constantly relax and contract in response to a chemical signal. That signal is a small, short-lived gas molecule called nitric oxide. When nitric oxide production is adequate, your vessels relax appropriately and blood flows freely. When production drops, your vessels remain slightly constricted, your heart works harder than it should, and your pressure climbs.
The production of nitric oxide in the human body follows a predictable curve over a lifetime. It peaks in the early twenties. By age 40, the average healthy adult is producing roughly half of what they produced at peak. By age 60, approximately fifteen percent.
By the time someone is sitting in an appointment being told they have stage 1 or stage 2 hypertension, the underlying decline in their nitric oxide production has, in almost every case, been quietly progressing for two decades. This is not the only cause of age-related hypertension. It is, however, one of the most consequential ones, and one of the most addressable.
The Two Pathways
This is the part that gets technical, and I want to walk through it carefully because it is the part that matters for what comes next.
Your body produces nitric oxide through two separate biological pathways. Both contribute. Both are addressable through nutrition and supplementation.
The first is the L-arginine pathway. Your body takes the amino acid L-arginine and, using an enzyme called endothelial nitric oxide synthase (eNOS), converts it directly into nitric oxide inside the lining of your blood vessels. This is the on-demand system. It is what is supposed to keep your vessels appropriately relaxed minute to minute.
The second is the dietary nitrate pathway. You consume foods that are high in inorganic nitrate (leafy greens, beets, and a few other vegetables). The bacteria in your mouth and gut convert that nitrate first into nitrite, and then into nitric oxide. This is the slower, food-derived support system.
These pathways do not substitute for one another. They work in parallel. A healthy young person uses both at near-optimal levels. An older adult with creeping blood pressure usually has impairment in one or both.
Supporting only one pathway with a supplement is doing half the job. This is, in my experience, the single most common error in how the supplement category for cardiovascular support is designed. A beetroot-only product supports pathway two. A standard L-arginine product supports pathway one. A meaningful product supports both.
Why Most Commercial NO Supplements Do Not Move The Needle
When I evaluate a commercial cardiovascular formulation, I look at three things in this order. Form of the active ingredient. Dose of the active ingredient. Combination strategy.
Form of the active ingredient
Standard L-arginine and patented forms of L-arginine behave very differently in the body. Standard L-arginine is largely metabolized by the enzyme arginase before reaching the bloodstream in meaningful quantities. Bioavailability studies on plain L-arginine are well documented and the results are modest at best. A patented form called Nitrosigine, which pairs L-arginine with a stabilizing silicate compound, has been shown in published clinical studies to elevate blood arginine levels within thirty minutes of ingestion and to sustain those elevations for up to six hours per dose. That is, in functional terms, an order of magnitude better. Most products on the shelf use the cheaper, less bioavailable form.
Dose of the active ingredient
This is the issue I find most often, and it is the one that frustrates me most as a scientist. A label will list the correct ingredient. The dose in the capsule will be a small fraction of the dose used in the supporting clinical study. This is most common in proprietary blends, where the individual ingredient milligrams are hidden behind a total weight. If a product cannot disclose the dose of each individual ingredient, the working assumption should be that the dose is inadequate. Forty years in this industry has not produced an exception to that rule.
Combination strategy
A product that supports only the L-arginine pathway is leaving the dietary nitrate pathway unsupported. A product that includes only beetroot extract is leaving the L-arginine pathway unsupported. A meaningful cardiovascular product addresses both. Additionally, the arteries themselves must be flexible enough to respond to the nitric oxide signal once it is produced. Trans-resveratrol, at clinical dose, has substantial published evidence supporting arterial flexibility and flow-mediated dilation. A complete product should include it.
Most commercial cardiovascular supplements fail one or more of these three tests. A small number pass all three. The one I formulated, BloodFlow-7, was designed specifically to pass all three.
What I Formulated, And Why
BloodFlow-7 is the cardiovascular formulation I co-developed at Juvenon. I want to be transparent about that. This article is sponsored by Juvenon. I am their Chief Science Officer. I have a financial relationship with the product. I am also a scientist with forty years in the field and I would not put my name on a formulation I did not believe in.
The formula is built around four components, each at the dose used in the supporting clinical studies, with full label transparency and no proprietary blends.
Nitrosigine® (patented arginine plus inositol-stabilized silicate)
Addresses the L-arginine pathway. Clinical studies have shown a boost in nitric oxide production of approximately 230 percent within hours of the first dose, and sustained elevation of blood arginine levels for up to six hours per dose.
S7® botanical complex
Addresses the dietary nitrate pathway, plus broader endothelial support, via seven plant-derived polyphenol sources (green coffee, green tea, turmeric, tart cherry, blueberry, broccoli, kale). Provides a second route of nitric oxide production that does not depend on individual variability in oral microbiome.
Trans-resveratrol at clinical dose
Supports arterial flexibility and flow-mediated dilation. Published clinical research has shown an effect of up to 62 percent improvement in arterial dilation at clinical dose. This is the component that ensures the arteries can actually respond to the nitric oxide signal once it is produced.
BioPerine®
A standardized extract of black pepper used as a bioavailability enhancer. Ensures that the active ingredients above actually cross into the bloodstream rather than being metabolized or excreted.
Four components. Both pathways. Clinical doses. Full label transparency. Backed by peer-reviewed research from institutions including the Whitaker Cardiovascular Institute and San Francisco State University.
My Credentials, Briefly
Dr. Luke Bucci, PhD
- 40+ years in nutritional biochemistry, sports medicine, and clinical research
- PhD in Biomedical Sciences
- Chief Science Officer, Juvenon (longevity supplement research)
- Author of multiple peer-reviewed papers on cardiovascular and metabolic nutrition
- Has formulated supplement products used by professional athletes, clinicians, and over 500,000 Juvenon customers
- Has mapped 13 of Juvenon's 46 active nutrients directly to Nobel-Prize-winning research
What I Would Tell A Newly Diagnosed Patient
If you have just been diagnosed and you are sitting at home reading this, here is what I would say if you were sitting across from me.
One. Take your medication. Your physician prescribed it for a reason and it is doing meaningful work on two of the systems that produce your blood pressure. Do not stop taking it without speaking with your doctor.
Two. Do the lifestyle work. Reduce sodium. Move daily. Lose ten pounds if you have them to lose. Stop smoking. Drink moderately or not at all. None of this is new. All of it matters.
Three. Address the upstream systems your medication is not touching. Specifically, the nitric oxide system. Use a supplement that supports both pathways, at clinical dose, with a trans-resveratrol component, in a transparent formulation. There are not many products that meet all those criteria. I formulated one because I could not find one I was satisfied with on the market.
Four. Be patient. Real cardiovascular change is measured in months, not days. Give any intervention at least 60 to 90 days before evaluating it. Your Sunday morning readings, taken at the same time and in the same conditions each week, are your most reliable data point. Track them.
Five. Talk to your doctor. If your readings begin to trend downward, your doctor may need to adjust your medication. This is a conversation to have. The goal is not to keep adding interventions on top of each other. The goal is to address the systems that are actually impaired.
What People Are Saying After Reading This
These are verified customer reviews. 500,000+ customers are now on the formula. The hero SKU holds a 4.8-star average across 6,400+ verified reviews. Backed by peer-reviewed research and a 60-day money-back guarantee.
✓ The 60-Day Money-Back Guarantee
I have enough confidence in the formulation that Juvenon offers a 60-day full money-back guarantee. If you do not feel a meaningful difference in your energy, your workouts, your circulation, or your Sunday morning readings, return it for a full refund. Even the empty bottle is covered.
If You Want To Try The Formulation
I am not a marketer. I am a scientist. So I am not going to write a sales pitch here. What I will say is that if my forty years in this field have taught me anything, it is that addressing both nitric oxide pathways at clinical dose, with a trans-resveratrol component, in a transparent formulation, is one of the few interventions for newly diagnosed patients that has earned my professional confidence.
This article was written by Dr. Luke Bucci, PhD, Chief Science Officer at Juvenon. Dr. Bucci has a financial relationship with Juvenon and a direct role in the formulation of BloodFlow-7. Individual results vary. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Consult your healthcare provider before using supplements or changing prescribed medication.
- CB
- JS
- DH
- TM
- RP